Rare Disease

Latest News

Gene therapy, gene editing concept | image credit: vchalup - stock.adobe.com
Delandistrogene Moxeparvovec Fails to Meet Primary End Point in Phase 3 Study

November 15th 2024

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve function after 52 weeks.

Patients with SMA and their caregivers stand to benefit from shared decision-making processes | image credit: Intelligent Horizons - stock.adobe.com
Shared Decision-Making Is Essential Prior to SMA-Enhancing Treatments

November 8th 2024

SMA type is a strong predictor of some oral functioning in affected patients | image credit: RTimages - stock.adobe.com
Oral Function Impairment Varies Across Adult Patients With SMA

October 28th 2024

SMA spinal muscular atrophy | Image Credit: © Rochu_2008 - stock.adobe.com
Protein Level Correlates With Pediatric SMA Severity, Treatment Response

October 17th 2024

SMA puzzle pieces | image credit: Dzmitry - stock.adobe.com
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA

October 17th 2024

Exploring the Implementation of Quality Care Programs for Patients with Myeloproliferative Neoplasms

Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.

Exploring the Implementation of Quality Care Programs for Patients with Myeloproliferative Neoplasms peer exchange

More News

molecules
March 4th 2022

Case Studies Show Value of Flow Cytometry in MDS Diagnoses

Jared Kaltwasser
Investigators sought to show how individual cases could be clarified through the use of flow cytometry analysis.
one person highlighted in a crowd
March 2nd 2022

Report: Economic Burden of Rare Diseases Is 10 Times Higher Than Mass Market Diseases

Laura Joszt, MA
The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment is available.
Image of doctors filling out forms
February 28th 2022

How Prior Authorization Can Impact Patients With Rare Disease

Allison Inserro
The prior authorization process is a hurdle to getting care for individuals with rare diseases and limited options, according to a rheumatologist and a patient interviewed just before Rare Disease Day.
Picture of infant
February 26th 2022

Report: Alpelisib Treated Rare Disease in Infants With Tissue Overgrowth

AJMC Staff
A recent case report described the successful treatment of 2 young infants with PIK3CA-related overgrowth spectrum using the breast cancer drug alpelisib.
Clinician examining thyroid
February 23rd 2022

Autoimmune Diseases, Especially Hypothyroidism, Associated With MDS Risk

Jared Kaltwasser
Patients with histories of inflammatory bowel disease and systemic lupus erythematosus were also at elevated risks of myelodysplastic syndromes (MDS), the authors found.
Bone marrow
February 19th 2022

Bone Marrow Fibrosis Holds Potential as Independent Prognostic Factor in MDS

Rose McNulty
Myelodysplastic syndrome has a variety of clinical presentations, including bone marrow fibrosis. Previously, the presence of fibrosis has not been considered in disease risk scoring in MDS, but recent research suggests it may be a valuable risk factor.
Image of a woman with cancer
February 17th 2022

Ruxolitinib Improves OS in Patients With Myelofibrosis vs Hydroxyurea Alone

Rose McNulty
An update to the ERNEST study found a survival benefit in ruxolitinib for the treatment of myelofibrosis in both the first and second line vs hydroxyurea.
doctor and patient in hospital
February 11th 2022

Model Can Predict Overall Survival in Myelofibrosis After Ruxolitinib Treatment

Laura Joszt, MA
The model identified risk factors after 6 months of treatment for the purposes of predicting overall survival and identifying which patients could benefit from a shift in treatment.
FDA approved icon
February 7th 2022

FDA Approves Sutimlimab for Cold Agglutinin Disease

AJMC Staff
The drug will be marketed by Sanofi under the name Enjaymo; it is the first treatment approved for cold agglutinin disease.
Genes and cells
January 19th 2022

Expert Panel Suggests Multidisciplinary Approach to Monitoring hATTR Amyloidosis

Christina Mattina
Blood samples for lab testing
January 1st 2022

Ponatinib, High-Dose Chemo Combo Likely to Benefit High-risk BP-CML

Maggie L. Shaw
Survival rates for patients with blast-phase chronic myeloid leukemia (BP-CML) are notoriously poor, necessitating effective treatments to fill the care gap for this group who often survive less than 1 year.
Top 5 Rare Disease Articles 2021
December 20th 2021

Top 5 Most-Read Rare Disease Articles of 2021

Hayden E. Klein
The top 5 most-read rare disease articles of 2021 on AJMC.com highlighted research on medications, therapies, and diagnosing tools to treat myelofibrosis, hemophilia B, chronic graft-vs-host disease, necrotizing myopathy, and myeloproliferative neoplasms.
telehealth
December 19th 2021

Virtual Care Reduced Illness, Death Due to COVID-19 for Patients With Sickle Cell Disease

Laura Joszt, MA
As the pandemic wore on, fewer patients with sickle cell disease who did contract COVID-19 needed to be hospitalized.
Voxelotor for Sickle Cell Disease Wins FDA Nod for Patients as Young as 4
December 17th 2021

Voxelotor for Sickle Cell Disease Wins FDA Nod for Patients as Young as 4

Allison Inserro
The oral polymerization inhibitor, a first-in-class therapy for sickle cell disease, was first approved by the FDA for adults and pediatric patients 12 years of age and older in 2019.
Report Highlights Case of Shellfish Allergy–Induced Overlap Chronic GVHD Following SCT
December 12th 2021

Report Highlights Case of Shellfish Allergy–Induced Overlap Chronic GVHD Following SCT

Jaime Rosenberg
In a recent case report, researchers outlined the case of a patients with shellfish allergy–induced overlap chronic graft versus host disease (ocGVHD)—a case of GVHD that has components of both acute and chronic GVHD.
red cross
December 9th 2021

Study Examines Relapse Risk in GVHD After Allo-HCT Using 2 Therapy Options

Jared Kaltwasser
Despite the increase in relapse risk, 2-year survival for patients with graft-versus-host disease (GVHD) who received matched sibling donor (MSD) allogeneic hematopoietic cell transplant (allo-HCT) administered post-transplant cyclophosphamide remained similar compared with patients receiving cyclosporine A with methotrexate prophylactically.
brain graphic
December 7th 2021

Review Highlights Role of Clinical Pharmacology in Approvals of Past, Future Rare Neurological Disease Therapies

Jared Kaltwasser
Fifty-one therapies have been approved for rare neurological diseases since the FDA passed the Orphan Drug Act in 1983.
Pregnant woman
December 3rd 2021

Case Report Suggests Improved Outcomes of PV During Pregnancy With Cytoreductive Treatment, Aspirin

Jaime Rosenberg
According to the researchers, the case study suggests that better results are achieved when using cytoreductive treatment and low-dose aspirin.
FDA Extends Review for Pacritinib for Treatment of Myelofibrosis With Severe Thrombocytopenia
November 30th 2021

FDA Extends Review for Pacritinib for Treatment of Myelofibrosis With Severe Thrombocytopenia

AJMC Staff
CTI BioPharma's New Drug Application had previously been granted Priority Review. The PDUFA date was November 30.
Cancer gene therapy
November 24th 2021

Researchers Identify Novel Biomarker, Therapeutic Target for Polycythemia Vera

Jaime Rosenberg
The data set included 177 samples from polycythemia vera, essential thrombocytopenia, primary myelofibrosis, and healthy donors, from which the researchers found that MAPK14 was overexpressed in PV samples and was associated with more symptoms and worse outcomes.
broken office chair
November 17th 2021

Significant Amount of Patients Remain on Sick Leave 1 Year Following Allo-HSCT, Study Says

Jaime Rosenberg
The findings showed that between 2009 to 2016, 76% of the 122 patients included in the study were on sick leave a year following their allogeneic hematopoietic stem cell transplantation (allo-HSCT).
GVHD Insights Point to Importance of Immunometabolism to Control Disease
November 13th 2021

GVHD Insights Point to Importance of Immunometabolism to Control Disease

Jaime Rosenberg
According to the study authors, a growing number of findings from preclinical studies have suggested a focus on immunometabolism to modulate alloreactive donor T cell responses to control graft-versus-host disease (GVHD) and promote graft-versus-tumor effect.
Person in magnifying glass
November 12th 2021

Novel Treatment Approach for Ultrarare MDH2D Detailed in Patient Case

Jaime Rosenberg
To date, just 3 previous reports have detailed cases of mitochondrial malate dehydrogenase deficiency (MDH2D), and there are no known cures.
Blood for genetic sequencing
November 6th 2021

Whole Genome Sequencing Increased Discovery of Rare Disorders by 31% in UK Study

AJMC Staff
The authors backed plans for the United Kingdom to establish a national diagnostic program based on whole genome sequencing (WGS) to speed the time to diagnosis.
Patients With MPNs Face Higher Cardiovascular Risks, in Addition to AML Risk
October 30th 2021

Patients With MPNs Face Higher Cardiovascular Risks, in Addition to AML Risk

Jared Kaltwasser
A new analysis suggests physicians should be on the lookout for cardiovascular disease and other types of cancer, in addition to acute myeloid lymphom, when caring for patients with certain myeloproliferative neoplasms (MPNs).
Review: Treatment Options Expanding in GVHD After HSCT, but More Data Needed
October 26th 2021

Review: Treatment Options Expanding in GVHD After HSCT, but More Data Needed

Jared Kaltwasser
A new review article highlights some of the newest therapies available to treat graft-versus-host disease (GVHD), but the authors say there is insufficient data to draw broad conclusions.
graphic of gene alteration
October 23rd 2021

Early Results of Gene Therapy for Angelman Syndrome Look Promising

AJMC Staff
Angelman syndrome affects roughly 1 in every 20,000 children and it has no approved treatment.
graphic of health care cost image
October 22nd 2021

Health Care Costs for Patients With Rare Disease Greater Than Previously Estimated

AJMC Staff
Health care costs are 3 to 5 times greater for people with rare diseases compared with those without, according to a new study.
FDA Clears Thymus Tissue Product to Treat Congenital Athymia
October 11th 2021

FDA Clears Thymus Tissue Product to Treat Congenital Athymia

AJMC Staff
The product, called Rethymic, is composed of human allogeneic thymus tissue that is processed and cultured and then implanted into children born without a thymus to help reconstitute immunity.
Scale comparison
October 6th 2021

Ruxolitinib Has Cost-effectiveness, Survival Benefits for Myelofibrosis vs Competitors

Maggie L. Shaw
Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis.
<12345678910
...
30>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo